MuLV-based vectors pseudotyped with truncated HIV glycoproteins mediate specific gene transfer in CD4+ peripheral blood lymphocytes

Gene Therapy

Volumn 5, Issue 5, 1998, Pages 655-664

  Lodge, R ^a   Subbramanian, R A ^a   Forget, J ^a   Lemay, G ^a   Cohen, E A ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

CD4+ cells; Gene transfer; HIV Env; Retroviral vector

Indexed keywords

CD4 ANTIGEN; ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ARTICLE; CLONING VECTOR; GENE TRANSFER; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MURINE LEUKEMIA VIRUS; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REPORTER GENE; VIRUS PARTICLE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MURINAE; MURINE LEUKEMIA VIRUS; RNA VIRUSES;

EID: 0031832607     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300646     Document Type: Article

References (43)

1. Lever AM. Gene therapy for HIV infection. Brit Med Bull 1995; 51: 149-166.
2. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem 1993; 62: 191-217.
3. Maddon PJ et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain Cell 1986; 47: 333-348.
4. Miller DG, Edwards RH, Miller AD. Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci USA 1994; 91: 78-82.
5. Miller DG, Miller AD. A family of retroviruses that utilize related phosphate transporters for cell entry. J Virol 1994; 68: 8270-8276.
6. Weiss RA, Tailor CS. Retrovirus receptors. Cell 1995; 82: 531-533.
7. Kavanaugh MP et al. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci USA 1994; 91: 7071-7075.
8. Albritton LM, Tseng L, Scadden D, Cunningham JM. A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell 1989; 57: 659-666.
9. Burns JC et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90: 8033-8037.
10. Dong J, Roth MG, Hunter E. A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J Virol 1992; 66: 7374-7382.
11. Schnierle BS, Groner B. Retroviral targeted delivery. Gene Therapy 1996; 3: 1069-1073.
12. Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 1995; 92: 9747-9751.
13. Somia NV, Zoppe M, Verma IM. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci USA 1995; 92: 7570-7574.
14. Palu G. Combined strategies for gene therapy of AIDS. Gene Therapy 1997; 4: 179-180.
15. Lever AM. HIV and other lentivirus-based vectors. Gene Therapy 1996; 3: 470-471.
16. Johnson JE, Schnell MJ, Buonocore L, Rose JK. Specific targeting to CD4(+) cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol 1997; 71: 5060-5068.
17. Lusso P et al. Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science 1990; 247: 848-852.
18. Landau NR, Page KA, Littman DR. Pseudotyping with human T cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol 1991; 65: 162-169.
19. Landau NR, Littman DR. Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol 1992; 66: 5110-5113.
20. Spector DH et al. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol 1990; 64: 2298-2308.
21. Heng MC, Heng SY, Allen SG. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994, 343: 255-258.
22. + cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 1996; 70: 2581-2585.
23. Lodge R et al. Two distinct oncornaviruses harbor an intracytoplasmic tyrosine-based basolateral targeting signal in their viral envelope glycoprotein. J Virol 1997; 71: 5696-5702.
24. Hunter E. Macromolecular interactions in the assembly of HIV and other retroviruses. Semin Virol 1994; 5: 71-83.
25. Dorfman T, Mammano F, Haseltine WA, Gottlinger HG. Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1994; 68: 1689-1696.
26. Yu X et al. The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol 1992; 66: 4966-4971.
27. Freed EO, Martin MA. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix J Virol 1995; 69: 1984-1989.
28. Mammano F et al. Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains. J Virol 1995; 69: 3824-3830.
29. Freed EO, Martin MA. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 1996; 70: 341-351.
30. + cells. J Virol 1997; 71: 3341-3345.
31. Schnierle BS et al. Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 1997; 94: 8640-8645.
32. Lodge R et al. The intracytoplasmic domain of gp41 mediates polarized budding of human immunodeficiency virus type 1 in MDCK cells. J Virol 1994; 68: 4857-4861.
33. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J Virol 1992; 66: 2232-2239.
34. Yu X, Yu QC, Lee TH, Essex M. The C-terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle. J Virol 1992; 66: 5667-5670.
35. Cosset FL, Russell SJ Targeting retrovirus entry Gene Therapy 1996; 3: 946-956.
36. Soneoka Y et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23: 628-633.
37. Lodge R, Lalonde JP, Lemay G, Cohen EA. The membrane- proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells. EMBO J 1997; 16: 695-705.
38. Yao XJ, Göttlinger H, Haseltine WA, Cohen EA. Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export. J Virol 1992; 66: 5119-5126.
39. Chesebro B, Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 1988; 62: 3779-3788.
40. Goff S, Traktman P, Baltimore D. Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. J Virol 1981; 38: 239-248.
41. Lee MH, Sano K, Morales FE, Imagawa DT. Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus. J Clin Microbiol 1987; 25: 1717-1721.
42. Bunnell BA et al. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci USA 1995; 92: 7739-7743.
43. Kobinger GP et al. Enhancement of retroviral production from packaging cell lines expressing the human immunodeficiency type 1 vpu gene. Gene Therapy 1997; 4: 868-874.